About Adaptive Biotechnologies Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune system into clinical products to diagnose and treat disease. Quick Links Stock Governance Filings Press Releases Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA) 12-01-2022 at 7:30 AM EST Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference 11-21-2022 at 4:05 PM EST New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results 11-21-2022 at 7:30 AM EST VIEW ALL NEWS Upcoming Events & Presentations More events are coming soon. Past Events & Presentations Piper Sandler Healthcare Conference Nov 30, 2022 at 2:30 PM EST Listen to webcast Adaptive Biotechnologies Third Quarter Financial Results Nov 3, 2022 at 4:30 PM EDT Listen to webcast Adaptive Biotechnologies Q3 2022 Earnings Presentation 2.1 MB Morgan Stanley Global Healthcare Conference Sep 12, 2022 at 12:30 PM EDT Listen to webcast VIEW ALL EVENTS CHANGE VOLUME 52 week high 52 week LOW MARKET CAP Dec 2, 2022 10:22 PM ESTData Provided by Refinitiv. Minimum 15 minutes delayed.
